Australia markets closed

Pieris Pharmaceuticals, Inc. (PIRS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
11.68-0.03 (-0.26%)
At close: 04:00PM EDT
11.26 -0.42 (-3.60%)
Pre-market: 08:25AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 14.44M
Enterprise value -11.92M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.31
Price/book (mrq)0.54
Enterprise value/revenue -0.28
Enterprise value/EBITDA 1.14

Trading information

Stock price history

Beta (5Y monthly) 0.50
52-week change 3-81.75%
S&P500 52-week change 323.57%
52-week high 380.80
52-week low 310.88
50-day moving average 313.70
200-day moving average 317.54

Share statistics

Avg vol (3-month) 312.64k
Avg vol (10-day) 333.44k
Shares outstanding 51.24M
Implied shares outstanding 61.24M
Float 8764.82k
% held by insiders 17.43%
% held by institutions 139.46%
Shares short (15 Apr 2024) 4301
Short ratio (15 Apr 2024) 40.02
Short % of float (15 Apr 2024) 40.02%
Short % of shares outstanding (15 Apr 2024) 40.02%
Shares short (prior month 15 Mar 2024) 4519

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:80
Last split date 323 Apr 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -57.33%
Operating margin (ttm)-422.02%

Management effectiveness

Return on assets (ttm)-14.76%
Return on equity (ttm)-89.76%

Income statement

Revenue (ttm)42.81M
Revenue per share (ttm)38.03
Quarterly revenue growth (yoy)-77.80%
Gross profit (ttm)N/A
EBITDA -13.94M
Net income avi to common (ttm)-24.54M
Diluted EPS (ttm)-21.60
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)26.37M
Total cash per share (mrq)21.32
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)3.24
Book value per share (mrq)21.64

Cash flow statement

Operating cash flow (ttm)-53.82M
Levered free cash flow (ttm)-26.68M